228 related articles for article (PubMed ID: 15058313)
1. Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics.
Baptista T; Zárate J; Joober R; Colasante C; Beaulieu S; Páez X; Hernández L
Curr Drug Targets; 2004 Apr; 5(3):279-99. PubMed ID: 15058313
[TBL] [Abstract][Full Text] [Related]
2. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.
Baptista T; Kin NM; Beaulieu S; de Baptista EA
Pharmacopsychiatry; 2002 Nov; 35(6):205-19. PubMed ID: 12518268
[TBL] [Abstract][Full Text] [Related]
3. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
Newcomer JW
CNS Drugs; 2005; 19 Suppl 1():1-93. PubMed ID: 15998156
[TBL] [Abstract][Full Text] [Related]
4. Effects of antipsychotic medications on appetite, weight, and insulin resistance.
Deng C
Endocrinol Metab Clin North Am; 2013 Sep; 42(3):545-63. PubMed ID: 24011886
[TBL] [Abstract][Full Text] [Related]
5. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological management of atypical antipsychotic-induced weight gain.
Baptista T; ElFakih Y; Uzcátegui E; Sandia I; Tálamo E; Araujo de Baptista E; Beaulieu S
CNS Drugs; 2008; 22(6):477-95. PubMed ID: 18484791
[TBL] [Abstract][Full Text] [Related]
7. Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
[TBL] [Abstract][Full Text] [Related]
8. TNF-α -308 G>A polymorphism and weight gain in patients with schizophrenia under long-term clozapine, risperidone or olanzapine treatment.
Huang HH; Wang YC; Wu CL; Hong CJ; Bai YM; Tsai SJ; Liou YJ
Neurosci Lett; 2011 Oct; 504(3):277-80. PubMed ID: 21967963
[TBL] [Abstract][Full Text] [Related]
9. [Metabolic side effects of risperidone in early onset schizophrenia].
Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
[TBL] [Abstract][Full Text] [Related]
10. Body weight gain induced by antipsychotic drugs: mechanisms and management.
Baptista T
Acta Psychiatr Scand; 1999 Jul; 100(1):3-16. PubMed ID: 10442434
[TBL] [Abstract][Full Text] [Related]
11. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
12. The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain?
Deng C; Weston-Green K; Huang XF
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):1-4. PubMed ID: 19922755
[TBL] [Abstract][Full Text] [Related]
13. The metabolic syndrome during atypical antipsychotic drug treatment: mechanisms and management.
Baptista T; De Mendoza S; Beaulieu S; Bermúdez A; Martinez M
Metab Syndr Relat Disord; 2004; 2(4):290-307. PubMed ID: 18370698
[TBL] [Abstract][Full Text] [Related]
14. Ameliorating antipsychotic-induced weight gain by betahistine: Mechanisms and clinical implications.
Lian J; Huang XF; Pai N; Deng C
Pharmacol Res; 2016 Apr; 106():51-63. PubMed ID: 26892184
[TBL] [Abstract][Full Text] [Related]
15. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.
Atmaca M; Kuloglu M; Tezcan E; Ustundag B
J Clin Psychiatry; 2003 May; 64(5):598-604. PubMed ID: 12755665
[TBL] [Abstract][Full Text] [Related]
16. Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians.
Hasnain M; Vieweg WV; Hollett B
Postgrad Med; 2012 Jul; 124(4):154-67. PubMed ID: 22913904
[TBL] [Abstract][Full Text] [Related]
17. Aripiprazole versus other atypical antipsychotics for schizophrenia.
Khanna P; Komossa K; Rummel-Kluge C; Hunger H; Schwarz S; El-Sayeh HG; Leucht S
Cochrane Database Syst Rev; 2013 Feb; (2):CD006569. PubMed ID: 23450570
[TBL] [Abstract][Full Text] [Related]
18. Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.
Simpson MM; Goetz RR; Devlin MJ; Goetz SA; Walsh BT
J Clin Psychiatry; 2001 Sep; 62(9):694-700. PubMed ID: 11681765
[TBL] [Abstract][Full Text] [Related]
19. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.
Mukundan A; Faulkner G; Cohn T; Remington G
Cochrane Database Syst Rev; 2010 Dec; (12):CD006629. PubMed ID: 21154372
[TBL] [Abstract][Full Text] [Related]
20. Olanzapine and risperidone effects on appetite and ghrelin in chronic schizophrenic patients.
Smith RC; Rachakonda S; Dwivedi S; Davis JM
Psychiatry Res; 2012 Oct; 199(3):159-63. PubMed ID: 22475524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
